FST 344 1mg*10vials

FST-344 1mg, 10 vials Product Description

The catalog specification is FST-344 at 1mg per vial in a 10-vial pack. The name requires caution: primary literature commonly uses FS344 for an alternatively spliced follistatin coding form or transgene associated with secretion of the FS315 isoform. A commercial vial labeled FST-344 is not automatically a mature 344-residue protein.

This listing does not provide sequence boundaries, precursor-processing state, expression host, glycosylation pattern, oligomeric state, or molecular mass. Without those attributes, the material could represent processed FS315, an unprocessed precursor, a fragment, or another recombinant construct. The exact 1mg-by-10 pack is preserved, but pack agreement cannot resolve molecular identity.

A defensible research listing should therefore present this as an unresolved follistatin-associated construct and make documentation status visible. Neutral use contexts include analytical identity work, comparison of construct documentation, and carefully controlled in-vitro investigations after the supplied molecule has been characterized. Gene-transfer findings should not be applied to an isolated vial because vector expression, processing, and tissue context differ fundamentally from a supplied protein preparation. No certificate values are available in this draft, and no statement about purity, sterility, endotoxin, stability, or analytical performance is implied. The item is for research use only and is not for human or veterinary use. Qualified laboratories should base protocol decisions on their own requirements, the verified identity of the received material, and lot-specific records rather than on a retail family name. Catalog inclusion does not establish fitness for a particular method. Receiving records, chain of custody, reference standards, and acceptance criteria should be defined by the laboratory and documented independently for every lot and presentation.

Research Material Profile

FST-344 1mg, 10 vials Research

FS344 in a nonhuman-primate vector study

PMID 20368179 reports an AAV1-FS344 gene-transfer experiment in cynomolgus macaques. The full paper explains that the human FS344 transgene encodes the secreted FS315 protein isoform, making the study especially useful for resolving nomenclature. Its observations arise from vector-mediated expression in animals, not from exposure to an isolated 1mg vial product. The source therefore supports the distinction between a 344-amino-acid coding form and the processed secreted product, but it does not identify what is present in this commercial item. Expression from a vector also involves biological processing that may not match a separately manufactured recombinant material. No inference about purity, activity, glycosylation, or lot content can be drawn from the study. The proper catalog conclusion is that construct and processing details remain necessary. Across interpretations, the publication supports only its reported material and measurements; it does not supply lot-level identity, composition, or quality evidence for this catalog presentation. (PubMed 20368179).

Human gene-transfer terminology

PMID 25322757 describes research using an AAV1.CMV.FS344 construct in a human gene-transfer setting. It confirms that FS344 appears in the literature as a transgene designation and provides a tightly bounded context for the studied construct. It does not establish the identity of a commercial protein, nor does it prove that a vial labeled FST-344 contains unprocessed FS344, secreted FS315, or any specific recombinant form. Findings from gene delivery cannot be transferred to a packaged protein because production, post-translational processing, exposure, and measurement conditions differ. The paper is included to clarify terminology, not to market an outcome. Before this catalog item can be aligned with a literature entity, product-specific sequence boundaries, expression system, molecular mass, and processing documentation would need to be reviewed. Across interpretations, the publication supports only its reported material and measurements; it does not supply lot-level identity, composition, or quality evidence for this catalog presentation. (PubMed 25322757).

Consequences of unresolved processing

The cited records demonstrate that “FS344” can identify a coding construct whose expressed product is discussed as FS315. That distinction materially affects molecular mass, domain boundaries, post-translational processing, and interpretation of any binding or cell-based assay. Researchers should avoid selecting assay conditions or reference standards based solely on the display name. The appropriate next step is lot-specific identity documentation that states what molecular species was manufactured and measured. Until such records exist, the item should remain categorized as an unresolved follistatin-associated research material. Neither gene-transfer paper tests this vial preparation, and neither supports assumptions about analytical quality, biological activity, or interchangeability with a mature follistatin isoform. Across interpretations, the publication supports only its reported material and measurements; it does not supply lot-level identity, composition, or quality evidence for this catalog presentation. (PubMed 20368179 · PubMed 25322757).

Evidence Boundaries

The cited publications describe defined study materials in particular biochemical, cell, animal, or controlled human research settings. They do not authenticate this catalog item, transfer analytical specifications to it, or establish that a nominally similar retail product is equivalent. Model observations must remain attached to the reported species, preparation, protocol, and endpoints. Where the title leaves sequence, chemical form, processing state, physical unit, formulation, or pack details unresolved, this draft leaves them unresolved as well. No purity percentage, sterility status, endotoxin result, stability period, or content assay is inferred. Any stronger conclusion requires lot-specific documentation and, where relevant, direct testing of the exact formulation.

FST-344 1mg, 10 vials References

8 curated medical and scientific references used for identity, mechanism, model, and assay context.

1. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.
   Kota J, Handy CR, Haidet AM, Montgomery CL, Eagle A, Rodino-Klapac LR, Tucker D, Shilling CJ, Therlfall WR, Walker CM, Weisbrode SE, Janssen PM, Clark KR, Sahenk Z, Mendell JR, Kaspar BK Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med. 2009;1(6):6ra15. doi:10.1126/scitranslmed.3000112. PMID:20368179.
   FS344 transgene nomenclature and nonhuman-primate gene transfer · AAV1-FS344 expression in cynomolgus macaques.
   View research source
2. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.
   Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015;23(1):192-201. doi:10.1038/mt.2014.200. PMID:25322757.
   Human AAV1.CMV.FS344 gene-transfer trial · Phase 1/2a gene-transfer research in participants with Becker muscular dystrophy.
   View research source
3. Follistatin-induced muscle hypertrophy in aged mice improves neuromuscular junction innervation and function.
   Iyer CC, Chugh D, Bobbili PJ, Iii AJB, Crum AE, Yi AF, Kaspar BK, Meyer KC, Burghes AHM, Arnold WD Follistatin-induced muscle hypertrophy in aged mice improves neuromuscular junction innervation and function. Neurobiol Aging. 2021;104:32-41. doi:10.1016/j.neurobiolaging.2021.03.005. PMID:33964607.
   Follistatin overexpression in aged mice · Viral follistatin expression in aged mouse muscle with neuromuscular measurements.
   View research source
4. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.
   Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology. 2006;147(7):3586-3597. doi:10.1210/en.2006-0089. PMID:16627583.
   Follistatin isoform bioactivity and binding · Cell-surface binding and ligand-neutralization assays comparing follistatin isoforms and FSTL3.
   View research source
5. Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay.
   Schneyer AL, Wang Q, Sidis Y, Sluss PM Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay. J Clin Endocrinol Metab. 2004;89(10):5067-5075. doi:10.1210/jc.2004-0162. PMID:15472207.
   Distribution of follistatin isoforms · Human specimen measurements using an FS315-specific immunoassay.
   View research source
6. Site-specific mutagenesis of human follistatin.
   Inouye S, Guo Y, Ling N, Shimasaki S Site-specific mutagenesis of human follistatin. Biochem Biophys Res Commun. 1991;179(1):352-358. doi:10.1016/0006-291x(91)91377-o. PMID:1883364.
   Human follistatin structure-function mutagenesis · Site-directed mutagenesis with in-vitro binding and activity characterization.
   View research source
7. Comparison of bioactivities, binding properties and intrafollicular levels of bovine follistatins.
   Glister C, Sunderland SJ, Boland MP, Ireland JJ, Knight PG Comparison of bioactivities, binding properties and intrafollicular levels of bovine follistatins. Reproduction. 2015;150(2):85-96. doi:10.1530/rep-15-0086. PMID:25964381.
   Follistatin isoform bioactivity comparison · Bovine follicular-fluid measurements and in-vitro binding/bioactivity assays.
   View research source
8. Detection of black market follistatin 344.
   Reichel C, Gmeiner G, Thevis M Detection of black market follistatin 344. Drug Test Anal. 2019;11(11-12):1675-1697. doi:10.1002/dta.2741. PMID:31758732.
   Analytical testing of products labeled follistatin 344 · Laboratory immunopurification, electrophoresis, and immunoblotting of 17 black-market products and standards.
   View research source